Renalytix PLC, a precision medicine diagnostics company, reported its Half Year Report for the six months ended 31 December 2025. Key highlights include
Revenue growth to $1.6 million, up from $1.3 million in the same period last year.
Addition of 58 new practice sites across four active regions in the US.
Expansion to five fully integrated EHR systems, up from two in the prior year.
Initiation of eight new integrations to expand access for approximately 10,000 eligible patients.
Extension of data integration pipelines to leading EMR platforms, including Epic Systems, Athenahealth, and eClinicalWorks.
Reduction in underlying EBITDA loss year-on-year, reflecting disciplined cost management.
Commencement of transition to a new laboratory facility to enhance capacity and improve gross margin.
Raising of $9.5 million through an oversubscribed placing and retail offer at a premium to the prior 6-month share price.
Post-period highlights include advancing contract discussions with major US diagnostic companies for national distribution, submission for publication of two-year outcomes data, progression of CE marking submission, and advancement of program milestones for inclusion in a major pharma drug trial.
The companys CEO, James McCullough, emphasized the progress made in expanding clinical adoption, advancing integration-led deployment, strengthening the clinical utility program, and enhancing operational efficiency. The company expects revenue acceleration in the second half of FY26 and improved momentum into FY27.
**Summary** Renalytix PLC reported revenue growth, expanded its clinical network, and made progress in integration and operational efficiency. The company raised additional capital and is positioning itself for scaled growth through national distribution partnerships and inclusion in a major pharma drug trial.
| Financial Metric | HY26 (Dec 2025) | HY25 (Dec 2024) | Year-on-Year Change |
|---|---|---|---|
| Revenue | $1.6 million | $1.3 million | 23.1% |
| Commercial Test Revenue | $1.1 million | $1.2 million | -8.3% |
| Life Sciences Revenue | $0.5 million | $0.1 million | 400% |
| Cost of Sales | $0.8 million | $0.8 million | 0% |
| Administrative Costs | $7.9 million | $8.0 million | -1.3% |
| Operating Loss | $7.1 million | $7.5 million | -5.3% |
| Underlying EBITDA Loss | $6.4 million | $7.2 million | -11.1% |
| Cash and Cash Equivalents | $6.1 million | $3.6 million | 69.4% |
| Debt (Convertible Note) | $4.7 million | $8.2 million | -42.7% |